Saturday, May 03, 2025 3:29:10 PM
Biosect, I was previously told that there are multiple quality levels that may be used in trials. Phase 1/2's are generally lower quality only intended to demonstrate some efficacy and safety and hopefully are sufficient to continue into full Phase 2 or 3 trials.
Phase 2 can be done with pivotal quality material, if you want the data to be considered for approval, but can be done with lesser grade.
Phase 3 must be done with pivotal quality material, essentially it's commercial quality, but can be made in equipment smaller than will be used for commercial production.
Companies may invest in building commercial capability early and utilize it at any time, but they can also wait until they feel confident of approval in time, as long as they have commercial capability ready for inspection when needed in the approval process.
Many companies, even the biggest BP's often choose to have CDMO's produce their products and not invest in commercial equipment themselves. It's a pay me now, pay me later situation, you make a little less if someone else does the production, but of course you also invest less. I don't believe that NWBO ever intended to own the entire production facility making the vaccine, even if LP does own a major interest in one of the CDMO's producing it.
Gary
Phase 2 can be done with pivotal quality material, if you want the data to be considered for approval, but can be done with lesser grade.
Phase 3 must be done with pivotal quality material, essentially it's commercial quality, but can be made in equipment smaller than will be used for commercial production.
Companies may invest in building commercial capability early and utilize it at any time, but they can also wait until they feel confident of approval in time, as long as they have commercial capability ready for inspection when needed in the approval process.
Many companies, even the biggest BP's often choose to have CDMO's produce their products and not invest in commercial equipment themselves. It's a pay me now, pay me later situation, you make a little less if someone else does the production, but of course you also invest less. I don't believe that NWBO ever intended to own the entire production facility making the vaccine, even if LP does own a major interest in one of the CDMO's producing it.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
